Trial Profile
A Randomized, Open Labelled Trial of Continuation of Adefovir Plus Lamivudine Versus Switching to Adefovir Plus Entecavir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Adefovir Plus Lamivudine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Adefovir; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms CAESAR
- Sponsors Asan Medical Center
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2010 The treatment duration changed from 52 weeks to 104 weeks according to ClinicalTrials.gov record.
- 02 Dec 2010 Planned End Date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.